Janux Therapeutics Inc Ordinary Shares JANX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $17.32
- Day Range
- $16.43–17.27
- 52-Week Range
- $12.12–35.34
- Bid/Ask
- $14.69 / $18.93
- Shares Outstanding
- 61.14M
- Market Cap
- $1.01B
- Volume/Avg
- 765,884 / 840,288
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 44.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 113
- Website
- https://www.januxrx.com
Valuation
|
Metric
|
JANX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.13 |
Price/Sales | 44.70 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
JANX
|
|---|---|
Quick Ratio | 16.25 |
Current Ratio | 16.35 |
Interest Coverage | — |
Quick Ratio
JANX
Profitability
|
Metric
|
JANX
|
|---|---|
Return on Assets (Normalized) | −6.45% |
Return on Equity (Normalized) | −6.85% |
Return on Invested Capital (Normalized) | −10.88% |
Return on Assets
JANX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|b&wC?F | LOCK|g@@% | $127B | |||
| Moderna Inc
MRNA
| LOCK|@!HB^Xt | LOCK|>^H | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|tGsKT#! | LOCK|!t>v& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|tnp<jl | LOCK|Wf | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@pwv?^t | LOCK|yM | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$Tqv?Bc | LOCK|>WlQ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!?W!JDN | LOCK|sV@@ | $27B | |||
| Incyte Corp
INCY
| LOCK|z^$>qz | LOCK|w^J | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$kwdqt | LOCK|%@d | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@p>ZQGs | LOCK|>& | $14B |
United States